2. Immunology/Inflammation
  3. CD47
  4. STI-6643

STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 blocks CD47-SIRPα interaction, and enables macrophage-mediated phagocytosis of tumor cells. STI-6643 shows anti-tumor activity in mouse lymphoma xenograft models. STI-6643 can be used for the research of Burkitt's lymphoma, solid tumors, relapsed or refractory tumors, and lymphoma. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

For research use only. We do not sell to patients.

CAS No. : 2376730-61-7

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

STI-6643 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

STI-6643 is a fully human IgG4 antibody that targets CD47. STI-6643 blocks CD47-SIRPα interaction, and enables macrophage-mediated phagocytosis of tumor cells. STI-6643 shows anti-tumor activity in mouse lymphoma xenograft models. STI-6643 can be used for the research of Burkitt's lymphoma, solid tumors, relapsed or refractory tumors, and lymphoma. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)[1][2].

Isotype

Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

CD47
In Vitro

STI-6643 binds to human CD47 with a Kd of 76 nM, with lower affinity for cynomolgus (177 nM) and canine (134 nM) CD47 antigens[1].
STI-6643 (25 min) binds dose-dependently to human MDA-MB-231 (EC50 ~30.0 µg/mL), human RAJI (EC50 6.64 µg/mL), canine OSCA-40 (EC50 ~30.0 µg/mL), and canine OSCA-78 (EC50 ~30.0 µg/mL) cancer cells[1].
STI-6643 (0.09-200 µg/mL; 15 min) dose-dependently blocks the CD47/SIRPα interaction on human CCRF-CEM cells with an IC50 of 3.65 µg/mL, without reaching saturation at concentrations up to 200 µg/mL[1].
STI-6643 (0.0001-10 µg/mL; 30 min) enhances macrophage-mediated phagocytosis of human RAJI-GFP cells[1].
STI-6643 (1.5625-50 µg/mL) does not exhibit direct tumor cell killing activity on human CCRF-CEM leukemia cells[1].
STI-6643 (100 µg/mL; 25 min) exhibits negligible binding to human (EC50 = 11.76 µg/mL) and cynomolgus monkey (EC50 = 20.32 µg/mL) RBCs, with slightly stronger binding to canine RBCs (EC50 = 5.10 µg/mL)[1].
STI-6643 (0.001-300 µg/mL; 20 h) does not induce hemagglutination of human or cynomolgus monkey RBCs at concentrations up to 300 µg/mL, and exhibits weak, 100-fold less potent hemagglutination activity than Hu5F9 in canine RBCs[1].
STI-6643 (0.001-100 µg/mL; 3 days) preserves human T cell survival and functionality in a superantigen stimulation assay, with minimal impact on IFN-γ secretion[1].
STI-6643 (0.001-500 µg/mL; 6 days) preserves the survival of human CD4+, CD8+, CD19+, and CD56+ immune cells[1].
STI-6643 (2.5-5 ng/mL; 30 min) in combination with Rituximab (HY-P9913) enhances macrophage-mediated phagocytosis of human RAJI-GFP cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

STI-6643 Related Antibodies
In Vivo

STI-6643 (0.1-60 mg/kg; i.v.; 3x/week; 2 consecutive weeks) exhibits potent dose-dependent anti-tumor activity and survival benefits in a mouse disseminated Burkitt's lymphoma xenograft model[1].
STI-6643 (20 mg/kg; i.v.; 3x/week; 2 consecutive weeks) in combination with Rituximab enhances anti-tumor activity and survival in a mouse disseminated Burkitt's lymphoma xenograft model[1].
STI-6643 (10 mg/kg; s.c.; 6 doses on days 6, 8, 10, 13, 15 and 17) preserves functional human T cells in a mouse xenograft GVHD model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Fox Chase/SCID mice (6-8 weeks old) intravenously injected with RAJI-Fluc cells[1]
Dosage: 0.1; 1; 10; 30; 60 mg/kg
Administration: i.v.; 3x/week; 2 consecutive weeks
Result: Reduced systemic tumor bioluminescence flux to levels comparable to Hu5F9 at 30 mg/kg.
Produced a 73% survival rate at 30 mg/kg.
Maintained healthy body weights in most animals at 30 mg/kg.
Significantly inhibited systemic tumor expansion and prolonged survival at 10 mg/kg.
Produced significant anti-tumor activity and survival in less aggressive tumor growth conditions at 1 mg/kg.
Showed no significant anti-tumor activity in more aggressive tumor growth conditions at 0.1 mg/kg.
Significantly prolonged survival at 60 mg/kg.
Animal Model: Fox Chase/SCID mice (6-8 weeks old) intravenously injected with RAJI-Fluc cells[1]
Dosage: 20 mg/kg
Administration: i.v.; 3x/week; 2 consecutive weeks
Result: Showed improved anti-tumor activity compared to either monotherapy when combined with rituximab.
Achieved an 88% endpoint survival rate.
Caused no adverse events or toxicity during the study.
Animal Model: NSG-Tg (hIL-15) mice (6-8 weeks old) intraperitonealy injected with human PBMCs on day -6, and subcutaneously injected with MDA-MB-231 cells on day 0[1]
Dosage: 10 mg/kg
Administration: s.c.; 6 doses on days 6, 8, 10, 13, 15 and 17
Result: Caused a ~50% decrease in circulating CD3+ T cells compared to isotype control.
Re-established a physiological CD4:CD8 ratio of 2:1.
Did not alter GVHD development kinetics .
Clinical Trial
Gene ID

961  [NCBI]

Accession

Q08722-1
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[STI-6643]
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
  • Immobilized CD47 Protein, Human (HEK293, HY-P72917) can bind STI-6643. The EC50 for this effect is 161.5 ng/mL.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

STI-6643 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

STI-66432376730-61-7STI6643STI 6643CD47Cluster of Differentiation 47MER6OA3CCRF-CEMsolid tumorslymphomaRAJIMDA-MB-231macrophagesSIRPαBurkitt's lymphomaT cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
STI-6643
Cat. No.:
HY-P991057
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.